High Insider Ownership Growth Stocks On The ASX In June 2024

In This Article:

Amidst a backdrop of geopolitical tensions impacting the Australian stock market, as evidenced by the slight downturn in ASX futures, investors continue to navigate through fluctuating global and domestic economic signals. In such an environment, stocks with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the company best—its leaders and key stakeholders.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Hartshead Resources (ASX:HHR)

13.9%

86.3%

Cettire (ASX:CTT)

28.7%

29.9%

Gratifii (ASX:GTI)

14.9%

112.4%

Acrux (ASX:ACR)

14.6%

115.3%

Doctor Care Anywhere Group (ASX:DOC)

28.4%

96.4%

Plenti Group (ASX:PLT)

12.8%

106.4%

Hillgrove Resources (ASX:HGO)

10.4%

45.4%

Change Financial (ASX:CCA)

26.6%

85.4%

Botanix Pharmaceuticals (ASX:BOT)

11.4%

120.9%

Liontown Resources (ASX:LTR)

16.4%

63.9%

Click here to see the full list of 90 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Kogan.com

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kogan.com Ltd is an online retailer based in Australia, with a market capitalization of approximately A$448.41 million.

Operations: The company generates revenue through its segments: Mighty Ape in Australia (A$11.39 million), Kogan Parent in Australia (A$274.85 million), Mighty Ape in New Zealand (A$142.52 million), and Kogan Parent in New Zealand (A$33.40 million).

Insider Ownership: 19.8%

Kogan.com recently became profitable and is trading at 57.6% below its estimated fair value, highlighting potential underpricing. While its revenue growth of 6% per year is modest, it surpasses the Australian market average. More impressively, earnings are expected to surge by 35.07% annually over the next three years, outpacing broader market growth significantly. High insider ownership aligns leadership with shareholder interests, although there's no recent insider trading activity to report.

ASX:KGN Ownership Breakdown as at Jun 2024
ASX:KGN Ownership Breakdown as at Jun 2024

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited, operating in Australia, the United States, Singapore, and Switzerland, focuses on developing regenerative medicine products with a market capitalization of approximately A$1.24 billion.

Operations: The company generates revenue primarily from its development of adult stem cell technology platform, totaling A$7.47 million.